IL131957A - Stable complexes of poorly soluble compounds - Google Patents

Stable complexes of poorly soluble compounds

Info

Publication number
IL131957A
IL131957A IL13195799A IL13195799A IL131957A IL 131957 A IL131957 A IL 131957A IL 13195799 A IL13195799 A IL 13195799A IL 13195799 A IL13195799 A IL 13195799A IL 131957 A IL131957 A IL 131957A
Authority
IL
Israel
Prior art keywords
poorly soluble
soluble compounds
stable complexes
complexes
stable
Prior art date
Application number
IL13195799A
Other languages
English (en)
Other versions
IL131957A0 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL131957(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL131957A0 publication Critical patent/IL131957A0/xx
Publication of IL131957A publication Critical patent/IL131957A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13195799A 1998-09-22 1999-09-16 Stable complexes of poorly soluble compounds IL131957A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10133698P 1998-09-22 1998-09-22
US13653199P 1999-05-28 1999-05-28

Publications (2)

Publication Number Publication Date
IL131957A0 IL131957A0 (en) 2001-03-19
IL131957A true IL131957A (en) 2005-06-19

Family

ID=26798138

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13195799A IL131957A (en) 1998-09-22 1999-09-16 Stable complexes of poorly soluble compounds

Country Status (32)

Country Link
US (1) US6350786B1 (cs)
EP (1) EP0988863B2 (cs)
JP (5) JP2000095708A (cs)
KR (1) KR100362019B1 (cs)
CN (1) CN1201821C (cs)
AR (2) AR022096A1 (cs)
AT (1) ATE265232T1 (cs)
AU (1) AU770745B2 (cs)
BR (1) BR9904283A (cs)
CA (1) CA2282906C (cs)
CO (1) CO5140077A1 (cs)
CZ (1) CZ300215B6 (cs)
DE (1) DE69916733T3 (cs)
DK (1) DK0988863T4 (cs)
ES (1) ES2218918T5 (cs)
HR (1) HRP990287B1 (cs)
HU (1) HU228341B1 (cs)
ID (1) ID24034A (cs)
IL (1) IL131957A (cs)
MA (1) MA26692A1 (cs)
MY (1) MY124377A (cs)
NO (1) NO326928B1 (cs)
NZ (1) NZ337884A (cs)
PE (1) PE20001049A1 (cs)
PL (1) PL202757B1 (cs)
PT (1) PT988863E (cs)
RS (1) RS50193B (cs)
RU (1) RU2240827C2 (cs)
SG (1) SG97131A1 (cs)
SI (1) SI0988863T2 (cs)
TR (1) TR199902324A3 (cs)
TW (1) TWI234465B (cs)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
CO5210860A1 (es) * 1999-10-01 2002-10-30 Hoffmann La Roche Nuevos derivados de pirimidina-2,4,6-triona
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
CA2409003C (en) * 2000-05-16 2010-10-19 Ortho-Mcneil Pharmaceutical, Inc. Process for coating medical devices using super-critical carbon dioxide
US6482847B2 (en) 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
DK1401404T3 (da) * 2001-05-30 2008-08-11 Csir Fremgangsmåde til indkapsling af et aktivt stof
US20030044514A1 (en) * 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
BR0210530A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de drogas e poìimeros acìdicos neutralizados
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
IL162819A0 (en) 2002-02-01 2005-11-20 Pfizer Prod Inc Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
JP2006500349A (ja) 2002-08-12 2006-01-05 ファイザー・プロダクツ・インク 半順序薬剤およびポリマーの医薬組成物
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
CN100563658C (zh) 2003-11-14 2009-12-02 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
JP4947482B2 (ja) * 2003-11-14 2012-06-06 味の素株式会社 フェニルアラニン誘導体の徐放性経口投与製剤
EP1735007A2 (en) * 2004-04-01 2006-12-27 F.Hoffmann-La Roche Ag Cyclodextrin inclusion complexes of pyrimidine-2,4,6-triones
AR049915A1 (es) * 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
WO2006070845A1 (ja) * 2004-12-28 2006-07-06 Eisai R & D Management Co., Ltd. 速崩壊性錠剤及びその製造方法
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP1843798A2 (en) * 2005-01-27 2007-10-17 Corium International Inc., Hydrophylic biocompatible adhesive formulations and uses
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
WO2006123223A1 (en) * 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
MY147410A (en) * 2005-06-22 2012-11-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
US20080221047A1 (en) * 2006-12-27 2008-09-11 Astellas Pharma Inc., Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug
EP2155166A2 (en) * 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2011500724A (ja) * 2007-10-19 2011-01-06 パーデュ リサーチ ファンデーション 結晶性化合物の固体製剤
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
CR20170089A (es) * 2009-04-03 2017-07-17 Plexxikon Inc Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
PE20121327A1 (es) 2009-11-06 2012-10-18 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
KR20130126451A (ko) * 2010-05-31 2013-11-20 아스테라스 세이야쿠 가부시키가이샤 트라이아졸 화합물의 고체 분산체
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
WO2012110469A1 (en) 2011-02-17 2012-08-23 F. Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
ME02513B (me) 2011-06-20 2017-02-20 H Lundbeck As Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije
KR101774223B1 (ko) 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
IN2014CN02290A (cs) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
MX353970B (es) * 2011-10-14 2018-02-07 Array Biopharma Inc Dispersion solida.
AU2013234921A1 (en) 2012-03-23 2014-10-02 Array Biopharma Inc. Treatment of brain cancer
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
KR20150084873A (ko) 2012-11-19 2015-07-22 닥터 레디스 레보러터리즈 리미티드 Cetp 억제제의 약학적 조성물
CN105007899A (zh) * 2012-12-20 2015-10-28 卡希夫制药有限责任公司 用于提高生物利用度的口腔崩解片制剂
MY192032A (en) 2013-01-22 2022-07-24 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
US20160213575A1 (en) * 2013-09-11 2016-07-28 3M Innovative Properties Company Coating compositions, dental structures thereof and methods for generating contrast
US20160303102A1 (en) * 2013-12-05 2016-10-20 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
JP2018516262A (ja) * 2015-05-29 2018-06-21 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． イソトレチノインの経口医薬組成物
FI3447056T3 (fi) * 2016-12-13 2025-07-10 Transthera Sciences Nanjing Inc Multikinaasi-inhibiittoriyhdiste ja sen kidemuoto ja käyttö
WO2018201016A1 (en) 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
RU2725879C2 (ru) * 2018-07-26 2020-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
JP7583719B2 (ja) 2018-12-03 2024-11-14 ハー・ルンドベック・アクチエゼルスカベット ４－（（１Ｒ，３Ｓ）－６－クロロ－３－フェニル－２，３－ジヒドロ－１Ｈ－インデン－１－イル）－１，２，２－トリメチルピペラジン及び４－（（１Ｒ，３Ｓ）－６－クロロ－３－（フェニル－ｄ５）－２，３－ジヒドロ－１Ｈ－インデン－１－イル）－２，２－ジメチル－１－（メチル－ｄ３）ピペラジンのプロドラッグ
AU2021210974A1 (en) * 2020-01-24 2022-09-22 Handa Therapeutics, Llc Amorphous solid dispersions of dasatinib and uses thereof
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
JP7705715B2 (ja) 2020-03-03 2025-07-10 デクセリアルズ株式会社 画像表示装置の製造方法
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
PT83812B (en) * 1985-11-27 1988-03-15 Syntex Inc Process for preparing amorphous benzimidazole derivatives
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
JP2528706B2 (ja) † 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH0729926B2 (ja) † 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU1537292A (en) † 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
GB9511220D0 (en) † 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US6254889B1 (en) * 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
AU7106996A (en) † 1995-09-07 1997-03-27 Fuisz Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09208459A (ja) * 1996-02-07 1997-08-12 Eisai Co Ltd 溶解性を改良した製剤
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
AU3483497A (en) * 1996-06-28 1998-01-21 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
RS49965B (sr) 1998-03-17 2008-09-29 F.Hoffmann-La Roche Ag., Supstituisani bisindolmaleimidi za inhibiciju ćelijske proliferacije

Also Published As

Publication number Publication date
HU228341B1 (en) 2013-03-28
EP0988863B2 (en) 2009-03-18
KR20000023426A (ko) 2000-04-25
AU4880799A (en) 2000-03-23
SI0988863T1 (en) 2004-08-31
NO994583L (no) 2000-03-23
HRP990287B1 (en) 2004-12-31
NZ337884A (en) 2001-02-23
SG97131A1 (en) 2003-07-18
ID24034A (id) 2000-07-06
HK1026632A1 (en) 2000-12-22
DK0988863T3 (da) 2004-08-30
DE69916733D1 (de) 2004-06-03
CZ330499A3 (cs) 2000-04-12
DE69916733T2 (de) 2005-03-31
EP0988863B1 (en) 2004-04-28
CA2282906C (en) 2010-07-20
DK0988863T4 (da) 2009-06-08
ES2218918T5 (es) 2009-06-23
KR100362019B1 (ko) 2002-11-23
JP2013035875A (ja) 2013-02-21
JP6253135B2 (ja) 2017-12-27
NO994583D0 (no) 1999-09-21
CN1201821C (zh) 2005-05-18
HUP9903189A2 (hu) 2000-06-28
IL131957A0 (en) 2001-03-19
HRP990287A2 (en) 2000-06-30
RU2240827C2 (ru) 2004-11-27
CN1251312A (zh) 2000-04-26
CZ300215B6 (cs) 2009-03-18
RS50193B (sr) 2009-05-06
YU47399A (cs) 2002-08-12
TR199902324A2 (xx) 2000-04-21
HU9903189D0 (en) 1999-11-29
BR9904283A (pt) 2000-09-26
PL335592A1 (en) 2000-03-27
ES2218918T3 (es) 2004-11-16
JP2000095708A (ja) 2000-04-04
EP0988863A3 (en) 2000-08-09
AU770745B2 (en) 2004-03-04
JP2015187170A (ja) 2015-10-29
MA26692A1 (fr) 2004-12-20
AR080892A2 (es) 2012-05-16
PL202757B1 (pl) 2009-07-31
TR199902324A3 (tr) 2000-04-21
HUP9903189A3 (en) 2009-07-28
SI0988863T2 (sl) 2009-08-31
DE69916733T3 (de) 2009-09-24
JP2016196515A (ja) 2016-11-24
JP6534979B2 (ja) 2019-06-26
TWI234465B (en) 2005-06-21
MY124377A (en) 2006-06-30
PT988863E (pt) 2004-07-30
AR022096A1 (es) 2002-09-04
EP0988863A2 (en) 2000-03-29
ATE265232T1 (de) 2004-05-15
CO5140077A1 (es) 2002-03-22
JP2007224048A (ja) 2007-09-06
PE20001049A1 (es) 2000-10-17
NO326928B1 (no) 2009-03-16
CA2282906A1 (en) 2000-03-22
US6350786B1 (en) 2002-02-26

Similar Documents

Publication Publication Date Title
IL131957A0 (en) Stable complexes of poorly soluble compounds
HRP20000381B1 (en) Stable complexes of poorly soluble compounds
AU4580599A (en) Stable no-delivering compounds
HRP970237B1 (en) Inclusion complexes of aryl-heterocyclic salts
GB9711237D0 (en) Organomettallic Complexes
HUP0103349A3 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
GB9817118D0 (en) Pharmaceutical compounds
HUP0202477A3 (en) Use of phthalazine derivatives
PL347324A1 (en) Bridged metal complexes
GB9817623D0 (en) Pharmaceutical compounds
GB9810886D0 (en) Pharmaceutical compounds
IL139490A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
AU5047399A (en) Tetrahydroindolone derivatives as gabaaalpha5 ligands for enhancing cognition
AU3632400A (en) Metal complexes containing bridging heteroatom for olefin-polymerization-process
GB9800750D0 (en) Pharmaceutical compound
AU1488001A (en) Stabilized thyroxine compounds
GB9823847D0 (en) Pharmaceutical compounds
AU4222599A (en) Poly-oxyanions as anchoring agents for metal complexes
GB9823845D0 (en) Pharmaceutical compounds
GB9902399D0 (en) Compounds
ZA996045B (en) Stable complexes of poorly soluble compounds.
AU3739300A (en) Synthesis of vapol ligands
GB9817197D0 (en) Pharmaceutical compounds
GB9803605D0 (en) Schiffs base complexes
GB9810855D0 (en) Use of compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired